40-Hour Cardiac Arrest Survivor: ECMO Technology Offers Hope for Miraculous Recovery
Translated from Korean, summarized and contextualized by DistantNews.
TLDR
- A 40-year-old man in China miraculously survived after his heart stopped for 40 hours.
- He was treated with ECMO (Extracorporeal Membrane Oxygenation), which supported his heart and lung functions.
- The patient was discharged after 20 days with no critical after-effects, showcasing the advancement in medical technology.
In a remarkable display of modern medical prowess, a 40-year-old Chinese man has made a full recovery after his heart remained stopped for an astonishing 40 hours. This extraordinary case, reported by the South China Morning Post, highlights the life-saving capabilities of ECMO technology. Doctors at the Second Affiliated Hospital of Zhejiang University School of Medicine successfully revived the patient, identified as Mr. A, after conventional resuscitation efforts failed. The ECMO machine acted as an artificial heart and lungs, maintaining blood circulation and oxygenation while medical staff worked to restore the patient's own heart function. The successful application of ECMO, a complex and high-risk procedure, allowed Mr. A to regain spontaneous heart activity and ultimately be discharged after 20 days, free from debilitating complications like stroke or kidney failure. This case underscores the significant advancements in critical care medicine, offering a beacon of hope for patients facing seemingly insurmountable odds. While Western media might focus on the technological marvel, for many in China and across Asia, this represents a profound triumph of human resilience and medical dedication, demonstrating that even in the most dire circumstances, survival and recovery are possible.
This success is the result of advancements in medical technology and 24-hour monitoring by medical staff.
Originally published by Dong-A Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.